Details for Patent: 12,673,035
Which drugs does patent 12,673,035 protect, and when does it expire?
Patent 12,673,035 protects IQIRVO and is included in one NDA.
This patent has eleven patent family members in eleven countries.
Summary for Patent: 12,673,035
| Title: | Solid dosage forms of elafibranor |
| Abstract: | The present invention relates to formulations of elafibranor or a pharmaceutically acceptable salt or ester thereof; and uses thereof. In particular, the present invention relates to an oral solid dosage form comprising at least elafibranor or a pharmaceutically acceptable salt or ester thereof; a filler, a disintegrating agent and a binder. |
| Inventor(s): | Alice Roudot, Marie-Jeanne JOISSAINS |
| Assignee: | Genfit SA |
| Application Number: | US19/302,463 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 12,673,035
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | IQIRVO | elafibranor | TABLET;ORAL | 218860-001 | Jun 10, 2024 | RX | Yes | Yes | 12,673,035 | ⤷ Start Trial | Y | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,673,035
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2024231686 | ⤷ Start Trial | |||
| China | 120826225 | ⤷ Start Trial | |||
| Colombia | 2025012602 | ⤷ Start Trial | |||
| European Patent Office | 4676456 | ⤷ Start Trial | |||
| Israel | 322676 | ⤷ Start Trial | |||
| Jordan | P20250224 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
